SGLT2 抑制剂在心房颤动发生中作用的研究进展.

Diabetes and its complications are closely related to the high incidence rate of atrial fibrillation (AF). Sodium-glucose cotransporter-2 inhibitor (SGLT2i), as a new type of hypoglycemic drugs, can reduce the renal glucose threshold by inhibiting SGLT2 receptor and ultimately achieve the hypoglycemic effect by promoting urine glucose excretion. In addition to the hypoglycemic effect, SGLT2i also has a series of beneficial effects such as reducing blood pressure, reducing body weight, lowering blood uric acid and reducing proteinuria. SGLT2i can not only reduce the risk of cardiovascular death and heart failure, but also more and more evidence shows that SGLT2i plays an important role in reducing AF occurrence. This paper summarizes the potential role of SGLT2i in AF, and its related mechanisms, which provides a new way for the prevention and treatment of AF. [ABSTRACT FROM AUTHOR]